HK Stock MarketDetailed Quotes

01875 TOT BIOPHARM-B

Watchlist
  • 1.740
  • +0.140+8.75%
Market Closed Dec 27 16:08 CST
1.34BMarket Cap40.47P/E (TTM)

TOT BIOPHARM-B Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
Turnover
49.27%809.02M
58.69%520.6M
67.79%222.54M
76.54%780.63M
77.25%541.98M
80.24%328.06M
65.28%132.63M
479.34%442.18M
744.11%305.78M
686.87%182.02M
Operating income
58.69%520.6M
76.54%780.63M
80.24%328.06M
479.34%442.18M
686.87%182.02M
Cost of sales
----
-84.08%-143.7M
----
-188.76%-206.64M
----
-232.48%-78.06M
----
-46.49%-71.56M
----
-156.79%-23.48M
Operating expenses
-84.08%-143.7M
-188.76%-206.64M
-232.48%-78.06M
-46.49%-71.56M
-156.79%-23.48M
Gross profit
50.76%376.91M
54.87%573.99M
57.69%250M
1,248.97%370.62M
1,033.33%158.54M
Selling expenses
----
-40.08%-276.48M
----
-116.23%-441.02M
----
-181.60%-197.38M
----
-792.62%-203.95M
----
-525.70%-70.09M
Administrative expenses
----
-3.22%-32.11M
----
-9.14%-68.31M
----
-21.04%-31.1M
----
-11.10%-62.59M
----
4.19%-25.7M
Research and development expenses
----
7.82%-46.06M
----
31.28%-103.89M
----
28.89%-49.97M
----
29.59%-151.17M
----
20.82%-70.27M
Impairment and provision
----
1,868.96%9.45M
----
-1,823.12%-11.48M
----
152.00%480K
----
---597K
----
---923K
-Other impairment is provision
----
1,868.96%9.45M
----
-1,823.12%-11.48M
----
152.00%480K
----
---597K
----
---923K
Special items of operating profit
----
-88.46%1.55M
----
104.92%17.65M
----
798.05%13.39M
----
28.39%8.62M
----
156.05%1.49M
Operating profit
328.17%33.26M
15.40%-33.06M
-109.79%-14.58M
84.95%-39.08M
93.98%-6.95M
Financing income
----
70.74%2.18M
----
31.30%2.97M
----
207.95%1.28M
----
133.75%2.27M
----
-41.88%415K
Financing cost
----
-71.65%-3.88M
----
21.61%-5.18M
----
33.85%-2.26M
----
-167.50%-6.6M
----
-1,147.45%-3.42M
Share of profit from joint venture company
----
----
----
62.39%-2.5M
----
106.88%397K
----
-38,917.65%-6.63M
----
---5.77M
Earning before tax
308.15%31.56M
24.56%-37.76M
3.57%-15.16M
80.84%-50.05M
86.33%-15.72M
Tax
----
----
----
---1K
----
---1K
----
----
----
----
After-tax profit from continuing operations
308.13%31.56M
24.56%-37.76M
3.57%-15.16M
80.84%-50.05M
86.33%-15.72M
Earning after tax
209.30%35.4M
308.13%31.56M
145.24%7.41M
24.56%-37.76M
22.28%-32.39M
3.57%-15.16M
-247.46%-16.38M
80.84%-50.05M
76.57%-41.68M
86.33%-15.72M
Minority profit
----
----
----
----
----
----
----
---130K
----
----
Profit attributable to shareholders
209.30%35.4M
308.13%31.56M
145.24%7.41M
24.36%-37.76M
20.10%-32.39M
3.57%-15.16M
-247.46%-16.38M
80.89%-49.92M
77.21%-40.54M
86.33%-15.72M
Basic earnings per share
300.00%0.04
37.50%-0.05
33.33%-0.02
82.61%-0.08
85.00%-0.03
Diluted earnings per share
300.00%0.04
37.50%-0.05
33.33%-0.02
82.61%-0.08
85.00%-0.03
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
HKAS
Audit Opinions
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
Auditor
--
--
--
PricewaterhouseCoopers
--
--
--
PricewaterhouseCoopers
--
--
(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022
Turnover 49.27%809.02M58.69%520.6M67.79%222.54M76.54%780.63M77.25%541.98M80.24%328.06M65.28%132.63M479.34%442.18M744.11%305.78M686.87%182.02M
Operating income 58.69%520.6M76.54%780.63M80.24%328.06M479.34%442.18M686.87%182.02M
Cost of sales -----84.08%-143.7M-----188.76%-206.64M-----232.48%-78.06M-----46.49%-71.56M-----156.79%-23.48M
Operating expenses -84.08%-143.7M-188.76%-206.64M-232.48%-78.06M-46.49%-71.56M-156.79%-23.48M
Gross profit 50.76%376.91M54.87%573.99M57.69%250M1,248.97%370.62M1,033.33%158.54M
Selling expenses -----40.08%-276.48M-----116.23%-441.02M-----181.60%-197.38M-----792.62%-203.95M-----525.70%-70.09M
Administrative expenses -----3.22%-32.11M-----9.14%-68.31M-----21.04%-31.1M-----11.10%-62.59M----4.19%-25.7M
Research and development expenses ----7.82%-46.06M----31.28%-103.89M----28.89%-49.97M----29.59%-151.17M----20.82%-70.27M
Impairment and provision ----1,868.96%9.45M-----1,823.12%-11.48M----152.00%480K-------597K-------923K
-Other impairment is provision ----1,868.96%9.45M-----1,823.12%-11.48M----152.00%480K-------597K-------923K
Special items of operating profit -----88.46%1.55M----104.92%17.65M----798.05%13.39M----28.39%8.62M----156.05%1.49M
Operating profit 328.17%33.26M15.40%-33.06M-109.79%-14.58M84.95%-39.08M93.98%-6.95M
Financing income ----70.74%2.18M----31.30%2.97M----207.95%1.28M----133.75%2.27M-----41.88%415K
Financing cost -----71.65%-3.88M----21.61%-5.18M----33.85%-2.26M-----167.50%-6.6M-----1,147.45%-3.42M
Share of profit from joint venture company ------------62.39%-2.5M----106.88%397K-----38,917.65%-6.63M-------5.77M
Earning before tax 308.15%31.56M24.56%-37.76M3.57%-15.16M80.84%-50.05M86.33%-15.72M
Tax ---------------1K-------1K----------------
After-tax profit from continuing operations 308.13%31.56M24.56%-37.76M3.57%-15.16M80.84%-50.05M86.33%-15.72M
Earning after tax 209.30%35.4M308.13%31.56M145.24%7.41M24.56%-37.76M22.28%-32.39M3.57%-15.16M-247.46%-16.38M80.84%-50.05M76.57%-41.68M86.33%-15.72M
Minority profit -------------------------------130K--------
Profit attributable to shareholders 209.30%35.4M308.13%31.56M145.24%7.41M24.36%-37.76M20.10%-32.39M3.57%-15.16M-247.46%-16.38M80.89%-49.92M77.21%-40.54M86.33%-15.72M
Basic earnings per share 300.00%0.0437.50%-0.0533.33%-0.0282.61%-0.0885.00%-0.03
Diluted earnings per share 300.00%0.0437.50%-0.0533.33%-0.0282.61%-0.0885.00%-0.03
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards HKASHKASHKASHKASHKASHKASHKASHKASHKASHKAS
Audit Opinions ------Unqualified Opinion------Unqualified Opinion----
Auditor ------PricewaterhouseCoopers------PricewaterhouseCoopers----

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Heat List
HK
Overall
Symbol
Price
% Chg

No Data

Investment Theme Pharmaceutical Companies
Pharmaceutical Companies
Intraday-0.61%